The global AI in Biotechnology Market is witnessing remarkable momentum as biotechnology companies increasingly deploy artificial intelligence to accelerate scientific discovery, improve research efficiency, and transform healthcare innovation. According to a recent study by SNS Insider, the global AI in Biotechnology Market size valued at USD 3.91 Billion in 2025, is anticipated to grow to USD 22.50 Billion by 2035, registering a CAGR of 19.13% over the 2026–2035 forecast period. The combination of expanding biological datasets, rapid advances in machine learning, and growing investment in next-generation therapeutic development is creating significant opportunities across the biotechnology ecosystem.
Artificial Intelligence (AI) is now considered to be a strategic advantage that pharmaceuticals and biotech firms may employ in order to accelerate their development cycles and optimize their research. With the continuing development of computational systems, the adoption of predictive modeling, automation, and advanced algorithms in the processes of drug discovery, genomic sciences, and precision medicine is becoming increasingly common among pharmaceuticals and biotechs.
To Get Detailed Insights on the AI in Biotechnology Market – Request a Sample Report
AI-Driven Drug Innovation Reshapes Biotechnology Research
The application of artificial intelligence in the biotech industry has transformed the processes of target identification, analysis of genomic data, and clinical development optimization. Due to modern algorithms, researchers can analyze vast biological data faster than in traditional ways and use the results for making better decisions in the course of the product lifecycle.
There are also more interactions between biotech organizations, pharma producers, research centers, and technology companies, which promotes innovation. Besides, there are investments in AI drug discovery platforms and regulatory initiatives supporting validation of AI applications in clinical research.
Key Market Findings Highlight High-Growth Segments
By component, the Software segment dominated the AI in Biotechnology Market with a 48% market share in 2025, reflecting widespread adoption of AI platforms for molecular modelling, predictive analytics, and biological data interpretation. The Services segment is projected to record the fastest growth during the forecast period as organizations increasingly seek AI integration, consulting, and data management expertise.
By application, Drug Discovery & Development accounted for the largest share with 44% of market revenue in 2025, supported by growing adoption of AI for molecule screening, target identification, and research optimization. Clinical Trials & Optimization is expected to emerge as the fastest-growing application as sponsors prioritize faster, more efficient, and data-driven clinical studies.
Based on end user, Pharmaceutical Companies represented 46% of total market revenue in 2025 owing to substantial investments in AI-enabled research and personalized medicine initiatives. Meanwhile, CRO & CDMO organizations are anticipated to register the fastest expansion as outsourcing and AI-powered research services continue gaining traction.
Technology Investments and Precision Medicine Fuel Expansion
Demand for precision medicines has been spurring biotech firms to adopt AI-driven solutions that can process genetic data, biomarkers, and health data of patients. Such technologies help develop personalized medications and improve both patient selection and medication efficacy.
At the same time, constant advancements in deep learning, prediction modeling, and computational biology have proven beneficial for the market. With a need for minimizing R&D costs and maximizing the probability of clinical success, artificial intelligence becomes an integral part of biotech research strategies.
Regional Markets:
North America was still the leading regional market in 2025, generating close to 42% of the global revenue, attributed to high-quality research infrastructure, substantial pharmaceutical investments, and favorable innovation ecosystems. In North America, the contribution of the United States to regional revenues was about 92.8%. The value of the US AI in Biotechnology Market was projected to be USD 1.34 Billion in 2025 and is expected to grow to USD 6.98 Billion by 2035 at a 17.90% CAGR.
The Asia Pacific region will experience the fastest growth rate over 2025-2035, owing to the growing biotechnological research, digital transformation in healthcare, and increased government support of innovations in life sciences.
In Europe, the U.K. was contributing to 26.4% of regional revenues due to advanced pharmaceutical research and digital health initiatives. In emerging economies, Brazil was contributing 54.2% to the Latin American market, whereas the UAE accounted for 13.6% of the Middle East & Africa revenues.
Leading Companies Expand AI Capabilities Across Biotechnology
Competition continues to intensify as biotechnology and technology companies strengthen AI capabilities through strategic partnerships, acquisitions, and research investments. Major participants operating in the global AI in Biotechnology Market include NVIDIA Corporation, Illumina Inc., IBM Corporation, Recursion Pharmaceuticals, Insilico Medicine, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi S.A., Amgen Inc., Johnson & Johnson (Janssen), Bristol-Myers Squibb Company, Merck & Co., Inc., Gilead Sciences Inc., Biogen Inc., Abbott Laboratories, Tempus AI, Schrödinger Inc., and Exscientia plc.
An SNS Insider analyst Parry Kardani commented, "Artificial intelligence is rapidly becoming a core technology within biotechnology, enabling organizations to accelerate drug discovery, improve research accuracy, and unlock new opportunities in precision medicine. Companies investing in scalable AI platforms, high-quality biological data, and collaborative innovation will be well positioned to lead the next generation of healthcare breakthroughs."
About the Author
Get in touch
